Trial Profile
A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Glandular and epithelial neoplasms; Solid tumours
- Focus Pharmacodynamics
- 07 Jul 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
- 11 Jun 2015 Planned End Date changed from 1 Aug 2016 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 22 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.